Peak inspiratory flow in patients with moderate or severe COPD using the Almirall inhaler

H. Magnussen, H. Watz, I. Zimmermann, S. Macht, R. Greguletz, D. Jarreta, E. Garcia Gil (Grosshansdorf, Bad Homberg, Germany; Barcelona, Spain)

Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Session: Pathogenesis and treatment of asthma and COPD
Session type: Thematic Poster Session
Number: 3613
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Magnussen, H. Watz, I. Zimmermann, S. Macht, R. Greguletz, D. Jarreta, E. Garcia Gil (Grosshansdorf, Bad Homberg, Germany; Barcelona, Spain). Peak inspiratory flow in patients with moderate or severe COPD using the Almirall inhaler. Eur Respir J 2008; 32: Suppl. 52, 3613

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients
Source: Annual Congress 2012 - Asthma management
Year: 2012


Inspiratory flow rates at different levels of resistance in elderly COPD patients
Source: Eur Respir J 2008; 31: 78-83
Year: 2008



Inhaler technique and peak inspiratory flow rates in patients with acute exacerbated COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 557s
Year: 2007

Peak inspiratory flow rates in COPD patients with Easyhaler® dry powder inhaler
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009


Peak inspiratory flow (PIF) when using a dry powder inhaler in asthmatics and COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 99s
Year: 2001

Peak inspiratory flow measured at different inhaler resistances in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Inspiratory flow profiles of patients with severe COPD achieved through Autohaler, Diskus, Turbohaler and in vitro assessment of corresponding output characteristics
Source: Eur Respir J 2003; 22: Suppl. 45, 409s
Year: 2003

Low maximum inspiratory flow index in patients with inhaler therapy
Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses
Year: 2019


Evaluation of inspiratory flow rates in stable severe COPD patients
Source: Annual Congress 2010 - Respiratory muscle function and training in acute and chronic respiratory disease
Year: 2010

Analysis of peak inspiratory flow and use of dry powder inhalers in patients with chronic obstructive pulmonary disease
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019


Bronchodilator reversibility testing in COPD using an inspiratory peak flow meter
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007


Sequential evaluation of expiratory flow limitation, inspiratory muscle strength and spirometry in severe COPD exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 149s
Year: 2001

IPPB with temporary expiratory pressure (T-PEP) in surgical patients with COPD
Source: Annual Congress 2007 - Clinical applications of noninvasive ventilation
Year: 2007


The maximum of expiratory cough pressure at the mouth (MECP-m) correlate with the cough peak expiratory flow (CPEF) and the degree of obstruction in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 623s
Year: 2006

Effect of He-O2 breathing and inhaled salbutamol on expiratory flow limitation and dynamic hyperinflation in COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 197s
Year: 2002

The effect of tiotropium on exacerbations and airflow in patients with COPD
Source: Eur Respir J 2006; 27: 547-555
Year: 2006



Improvements in inspiratory capacity with tiotropium in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 491s
Year: 2002

Peak inspiratory flow in COPD: implications for the use of dry powder inhalers
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001

Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Respiratory structure and function
Year: 2008


NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease
Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Year: 2006